RxDoctor Payments Data
★ My doctorsLook up a doctor →

Alberto Corica Guinle, MD

Urology · Guayama, PRNPI 1336280429

Payments from drug & device makers

$787in general payments, 2019–2025

Across 18 payments — averaging $43.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Latin America, Inc.$211
  • Boston Scientific$141
  • Travere Therapeutics, Inc.$118
  • Amgen$83
  • Medtronic$72
  • AbbVie$71
  • plus $91 from 2 others

What the payments were for

  • Food & beverage$787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Olympus Latin America, Inc.2$211
Boston Scientific2$141
Travere Therapeutics, Inc.2$118
Amgen4$83
Medtronic1$72
AbbVie4$71
Astellas Pharma US Inc1$59
Ferring Pharmaceuticals Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$787 in reported general payments places this provider in the 30th percentile of 122 urology providers in Puerto Rico.

See all urology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024
$20,988
Medicare patients
48
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide53$756,029
Lupron DepotLeuprolide Acetate44$132,552
Bicalutamide761$20,093
Tamsulosin Hcl2,302$18,432
Tolterodine Tartrate ErTolterodine Tartrate205$15,540
Finasteride1,078$9,732
Alendronate Sodium735$4,430
Tolterodine Tartrate86$2,694
Ciprofloxacin Hcl433$2,063
Bethanechol Chloride35$1,744
Oxybutynin Chloride144$1,528
Tadalafil11$1,503
Silodosin13$931
Doxazosin Mesylate86$860
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim260$825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$59$756,02953 claims
AbbVieLupron Depot$71$132,55244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 122 urology providers in Puerto Rico.

Other urology in Guayama

See the full list for Puerto Rico →

Where these figures come from

Is this you, or does something look wrong? →